Friday, 10 July 2020
A major UK research study into the long-term health impacts of COVID-19 on hospitalised patients has been launched.
The PHOSP-COVID study has been awarded £8.4million jointly by UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR). This study is one of a number of COVID-19 studies that have been given urgent public health research status by the Department of Health and Social Care.
Gisli Jenkins, Professor of Experimental Medicine in the School of Medicine at the University of Nottingham, will share expertise with a national consortium of leading researchers and clinicians from across the UK to assess the impact of COVID-19 on patients’ health and their recovery.
Around 10,000 patients are expected to take part in the study led by the NIHR Leicester Biomedical Research Centre – a partnership of the University of Leicester and University Hospitals of Leicester NHS Trust, making it one of the largest comprehensive studies in the world to understand and improve the health of survivors after hospitalisation from COVID-19.
Professor Jenkins is an NIHR Research Professor with expertise in Respiratory medicine - particularly Pulmonary Fibrosis (Lung scarring). He is the lead for the Post COVID Lung Fibrosis working group of PHOSP-COVID.
Chris Brightling, Professor of Respiratory Medicine at the University of Leicester, Consultant Respiratory Physician at University Hospitals of Leicester NHS Trust, and chief investigator for the study said:
“As we emerge from the first wave of the pandemic, we have new insights into the acute phase of this disease but very little information about patients’ long term needs.
“It is vitally important that we rapidly gather evidence on the longer term consequences of contracting severe COVID-19 so we can develop and test new treatment strategies for them and other people affected by future waves of the disease.”
Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia and sadly even lost their lives. For those who were hospitalised and have since been discharged, it is not yet clear what the medical, psychological and rehabilitation needs for this group of patients will be to enable them to make as full a recovery as possible.
Patients on the study will be assessed using techniques such as advanced imaging, data collection and analysis of blood and lung samples, creating a comprehensive picture of the impact COVID-19 has had on longer term health outcomes across the UK.
The project is important because a large number of people who suffer from COVID-19 have persisting symptoms for a long period of time after the initial infection and the majority of those symptoms include breathlessness and fatigue which are symptoms that might indicate lung scarring. It is important that we find out whether scarring is a major problem after COVID infection as soon as possible if we are to develop strategies to treat it effectively.”
The PHOSP-COVID team will then develop trials of new strategies for clinical care, including personalised treatments for groups of patients based on the particular disease characteristics they show as a result of having COVID-19 to improve their long term health.
The PHOSP-COVID study is widely supported across the NIHR infrastructure, including the Translational Research Collaborations for respiratory, mental health, cardiovascular, dementia, and diet, exercise and nutrition, and many of the NIHR Biomedical Research Centres, which are set up to translate lab-based scientific breakthroughs into potential new treatments, diagnostics and medical technologies.
To follow the study as it develops, visit www.phosp.org.
Notes to editors:
The University of Nottingham
Ranked 18th in the UK by the QS World University Rankings 2023, University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
The University is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.The University is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.